120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
离子载体抗生素在卵巢癌中的治疗潜力：机制与前景
Authors Feng L , Wen W, Shujuan Y
Received 11 September 2025
Accepted for publication 29 December 2025
Published 20 January 2026 Volume 2026:18 566921
DOI https://doi.org/10.2147/CMAR.S566921
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Harikrishna Nakshatri
Li Feng,1 Wang Wen,2 Yao Shujuan3
1The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China; 2Tengzhou Central People’s Hospital, Tengzhou, Shandong, People’s Republic of China; 3Gynecology Department, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China
Correspondence: Wang Wen, Tengzhou Central People’s Hospital, Tengzhou, Shandong, People’s Republic of China, Email 925059557@qq.com Yao Shujuan, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China, Email 13064017834@163.com
Abstract: With over two-thirds of cases diagnosed at advanced stages, ovarian cancer is the deadliest gynecological cancer. In 70% of patients receiving standardized treatment, recurrence happens within 12– 24 months, leading to a 5-year survival rate below 35%. Patients with ovarian cancer now have a better outlook thanks to personalized precision treatment; however, treating advanced ovarian cancer remains challenging. The poor 5-year survival rate and disease recurrence in individuals with ovarian cancer are mainly caused by platinum resistance. Therefore, targeted screening for drugs that can not only inhibit the growth of ovarian cancer cells but also control their migration, invasion, and drug resistance is especially important to reduce the treatment challenges of ovarian cancer. Ionic carrier antibiotics have enhanced the resistance of several malignant tumors to chemotherapy and have shown anti-tumor properties. This article explores the development of ionic carrier antibiotic research in ovarian cancer to evaluate their potential role in the disease.
Keywords: ion carrier antibiotics, ovarian cancer, treatment, gynecology, cancer
1The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China; 2Tengzhou Central People’s Hospital, Tengzhou, Shandong, People’s Republic of China; 3Gynecology Department, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China
Correspondence: Wang Wen, Tengzhou Central People’s Hospital, Tengzhou, Shandong, People’s Republic of China, Email 925059557@qq.com Yao Shujuan, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People’s Republic of China, Email 13064017834@163.com
Abstract: With over two-thirds of cases diagnosed at advanced stages, ovarian cancer is the deadliest gynecological cancer. In 70% of patients receiving standardized treatment, recurrence happens within 12– 24 months, leading to a 5-year survival rate below 35%. Patients with ovarian cancer now have a better outlook thanks to personalized precision treatment; however, treating advanced ovarian cancer remains challenging. The poor 5-year survival rate and disease recurrence in individuals with ovarian cancer are mainly caused by platinum resistance. Therefore, targeted screening for drugs that can not only inhibit the growth of ovarian cancer cells but also control their migration, invasion, and drug resistance is especially important to reduce the treatment challenges of ovarian cancer. Ionic carrier antibiotics have enhanced the resistance of several malignant tumors to chemotherapy and have shown anti-tumor properties. This article explores the development of ionic carrier antibiotic research in ovarian cancer to evaluate their potential role in the disease.
Keywords: ion carrier antibiotics, ovarian cancer, treatment, gynecology, cancer